News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
749,562 Results
Type
Article (45667)
Company Profile (340)
Press Release (703537)
Multimedia
Podcasts (141)
Webinars (21)
Section
Business (212992)
Career Advice (2200)
Deals (37253)
Drug Delivery (132)
Drug Development (84631)
Employer Resources (178)
FDA (16984)
Job Trends (15678)
News (361417)
Policy (34657)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2644)
Accelerated approval (32)
Adcomms (33)
Allergies (145)
Alliances (52257)
ALS (177)
Alzheimer's disease (1706)
Antibody-drug conjugate (ADC) (336)
Approvals (17222)
Artificial intelligence (544)
Autoimmune disease (157)
Automation (37)
Bankruptcy (378)
Best Places to Work (11842)
BIOSECURE Act (22)
Biosimilars (200)
Biotechnology (195)
Bladder cancer (158)
Brain cancer (59)
Breast cancer (650)
Cancer (4919)
Cardiovascular disease (428)
Career advice (1854)
Career pathing (39)
CAR-T (291)
CDC (50)
Celiac Disease (2)
Cell therapy (769)
Cervical cancer (36)
Clinical research (72091)
Collaboration (1782)
Company closure (5)
Compensation (1174)
Complete response letters (66)
COVID-19 (2807)
CRISPR (95)
C-suite (854)
Cystic fibrosis (149)
Data (6245)
Decentralized trials (2)
Denatured (41)
Depression (140)
Diabetes (518)
Diagnostics (6793)
Digital health (45)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (262)
Drug pricing (218)
Drug shortages (34)
Duchenne muscular dystrophy (235)
Earnings (92256)
Editorial (60)
Employer branding (21)
Employer resources (158)
Events (121442)
Executive appointments (997)
FDA (20128)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1492)
Gene editing (205)
Generative AI (49)
Gene therapy (625)
GLP-1 (1077)
Government (4882)
Grass and pollen (7)
Guidances (385)
Healthcare (19204)
HIV (57)
Huntington's disease (45)
IgA nephropathy (85)
Immunology and inflammation (277)
Immuno-oncology (61)
Indications (105)
Infectious disease (3081)
Inflammatory bowel disease (195)
Inflation Reduction Act (14)
Influenza (111)
Intellectual property (247)
Interviews (344)
IPO (17088)
IRA (57)
Job creations (4177)
Job search strategy (1560)
JPM (68)
Kidney cancer (16)
Labor market (84)
Layoffs (602)
Leadership (37)
Legal (8580)
Liver cancer (93)
Longevity (15)
Lung cancer (665)
Lymphoma (380)
Machine learning (43)
Management (62)
Manufacturing (823)
MASH (171)
Medical device (13893)
Medtech (13945)
Mergers & acquisitions (21241)
Metabolic disorders (1365)
Multiple sclerosis (167)
NASH (20)
Neurodegenerative disease (335)
Neuropsychiatric disorders (95)
Neuroscience (2984)
Neurotech (1)
NextGen: Class of 2026 (6737)
Non-profit (4585)
Now hiring (65)
Obesity (666)
Opinion (306)
Ovarian cancer (167)
Pain (217)
Pancreatic cancer (225)
Parkinson's disease (291)
Partnered (35)
Patents (502)
Patient recruitment (488)
Peanut (59)
People (61405)
Pharmaceutical (100)
Pharmacy benefit managers (33)
Phase 1 (22487)
Phase 2 (31643)
Phase 3 (23704)
Pipeline (5221)
Policy (312)
Postmarket research (2687)
Preclinical (9480)
Press Release (68)
Prostate cancer (240)
Psychedelics (49)
Radiopharmaceuticals (288)
Rare diseases (879)
Real estate (6417)
Recruiting (72)
Regulatory (25714)
Reports (51)
Research institute (2457)
Resumes & cover letters (372)
Rett syndrome (27)
RNA editing (18)
RSV (83)
Schizophrenia (155)
Series A (246)
Series B (195)
Service/supplier (14)
Sickle cell disease (99)
Special edition (26)
Spinal muscular atrophy (163)
Sponsored (42)
Startups (3833)
State (2)
Stomach cancer (19)
Supply chain (111)
Tariffs (100)
The Weekly (98)
Vaccines (1041)
Venture capital (92)
Weight loss (456)
Women's health (89)
Worklife (19)
Date
Today (111)
Last 7 days (644)
Last 30 days (2185)
Last 365 days (30764)
2026 (3079)
2025 (31093)
2024 (36157)
2023 (40933)
2022 (52117)
2021 (56678)
2020 (55111)
2019 (47823)
2018 (36142)
2017 (33578)
2016 (33175)
2015 (39011)
2014 (32966)
2013 (28079)
2012 (30166)
2011 (30876)
2010 (28892)
Location
Africa (828)
Alabama (84)
Alaska (7)
Arizona (315)
Arkansas (14)
Asia (43145)
Australia (6849)
California (11297)
Canada (3293)
China (1151)
Colorado (479)
Connecticut (474)
Delaware (338)
Europe (92872)
Florida (1695)
Georgia (354)
Hawaii (3)
Idaho (61)
Illinois (877)
India (67)
Indiana (531)
Iowa (22)
Japan (436)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1394)
Massachusetts (8151)
Michigan (324)
Minnesota (629)
Mississippi (5)
Missouri (127)
Montana (31)
Nebraska (28)
Nevada (125)
New Hampshire (78)
New Jersey (3019)
New Mexico (31)
New York (2979)
North Carolina (1508)
North Dakota (8)
Northern California (5492)
Ohio (336)
Oklahoma (22)
Oregon (47)
Pennsylvania (2284)
Puerto Rico (24)
Rhode Island (47)
South America (1196)
South Carolina (66)
South Dakota (1)
Southern California (4393)
Tennessee (174)
Texas (1755)
United States (40274)
Utah (339)
Vermont (1)
Virginia (276)
Washington D.C. (82)
Washington State (926)
West Virginia (4)
Wisconsin (113)
Wyoming (2)
749,562 Results for "pact pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Roche Keeps the Deals Coming With up to $1.7B SangeneBio RNAi Pact
The alliance will add to Roche’s RNAi efforts, which include the hypertension candidate zilbesiran, partnered with Alnylam under a July 2023 agreement.
February 3, 2026
·
1 min read
·
Tristan Manalac
Gene editing
Lilly Leans Into Hearing Loss in $1.12B+ Gene Editing Pact With Seamless
The deal will help bolster Eli Lilly’s growing hearing loss portfolio, which is anchored by the gene therapy AK-OTOF.
January 28, 2026
·
2 min read
·
Tristan Manalac
Cell therapy
After Cell Therapy Retreat, Novo Offloads Technologies in Deepened Aspect Pact
Novo Nordisk pulled back from cell therapies last October, scrapping development of a type 1 diabetes therapy and laying off most employees working on this modality.
January 21, 2026
·
2 min read
·
Tristan Manalac
Inflammatory bowel disease
Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere
The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.
January 27, 2026
·
2 min read
·
Tristan Manalac
Cancer
Pfizer Searches for Novel Tumor-Selective Antigens With $865M+ Cartography Pact
Cartography will hunt for novel tumor antigens, which Pfizer can opt into and advance into clinical development.
January 7, 2026
·
2 min read
·
Tristan Manalac
Weight loss
Zealand Bets up to $2.5B in Metabolic Pact With Chinese Biotech
Also on Thursday, Zealand held its Capital Markets Day in London,
outlining the strategy
for its weight management franchise in the near-term, including launching five products by 2030.
December 11, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact
The deals will help Lilly diversify its portfolio that is heavily weighted on the obesity juggernaut tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss.
January 8, 2026
·
2 min read
·
Tristan Manalac
Inflammatory bowel disease
Roche Makes Preclinical IBD Play in $420M+ OMass Pact
The OMass partnership will boost Roche’s strategy in inflammatory bowel diseases, currently led by afimkibart, an anti-TL1A therapy the pharma obtained from its $7.1 billion acquisition of Telavant in 2023.
September 2, 2025
·
2 min read
·
Tristan Manalac
Obesity
Novo Ups Obesity Ante With $800M+ Deep Apple Pact for Oral, Non-Incretin Drugs
For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months after the Danish pharma’s amylin efforts underwhelmed investors.
June 11, 2025
·
3 min read
·
Tristan Manalac
Metabolic disorders
Lilly Makes $1.2B RNAi Pact With SangeneBio, Targets Metabolic Diseases
Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.
November 10, 2025
·
2 min read
·
Tristan Manalac
1 of 74,957
Next
